23 completed, 9 terminated, 3 unknown, 3 withdrawn. 24 Phase 2, 16 Phase 1, 2 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow FANG vaccine: new trials by email Literature Review of FANG vaccine trials Research Report on FANG vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous Tumour Vaccine Trial Radvax - Solid Tumor | Phase 1 | Recruiting | Vaxine Pty Ltd | 30 | 2023-02-10 | 2025-09-17 |
| Bioequivalence Study of Modafinil From Bravamax 200 mg Scored Tablets (Chemipharm Pharmaceutical Industries, Egypt) Versus Vigil 200 mg Tablets (Teva GmbH, Germany) Bravamax 200 mg (Modafinil), Vigil 200 mg (Modafinil) - Healthy | Phase 1 | Completed | Genuine Research Center, Egypt | 30 | 2022-11-15 | 2023-05-11 |
| A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide Vigil, Irinotecan, Temozolomide - Ewing Sarcoma, Ewing Family of Tumors | Phase 3 | Terminated | Gradalis, Inc. | 32 | 2018-08-21 | 2023-04-26 |
| A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers Vigil, Atezolizumab - Advanced Gynecological Cancers, Ovarian Cancer | Phase 2 | Completed | Gradalis, Inc. | 25 | 2017-05-31 | 2023-04-05 |
| Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers Vigil, Durvalumab - Breast Cancer, Ovarian Cancer | Phase 2 | Completed | Mary Crowley Medical Research Center | 13 | 2016-06-03 | 2021-01-27 |
| Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer Vigil™, Nivolumab - Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 2 | Withdrawn | Gradalis, Inc. | 2016-03-01 | 2017-07-31 | |
| A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma Vigil, Temozolomide, Irinotecan - Ewing's Sarcoma | Phase 2 | Completed | Gradalis, Inc. | 22 | 2016-02-10 | 2022-12-22 |
| Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma Vigil, Pembrolizumab - Melanoma Recurrent, Malignant Melanoma | Phase 1 | Completed | Gradalis, Inc. | 2 | 2015-10-01 | 2017-09-27 |
| A Trial of Vigil for Participants With Ovarian Cancer Vigil, Placebo - Ovarian Cancer, Ovarian Neoplasms | Phase 2 | Active not recruiting | Gradalis, Inc. | 92 | 2015-02-01 | 2025-10-29 |
| Use of Cell Therapy to Enhance Arthroscopic Knee Cartilage Surgery Autologous Cell, Standard microfracture arthroscopic surgery - Articular Cartilage Defect Grade III or IV of the Knee | Not applicable | Completed | Fondren Orthopedic Group L.L.P. | 48 | 2013-02-01 | 2019-01-10 |
| Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma cyclophosphamide, aldesleukin, autologous tumor cell vaccine - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Completed | Fred Hutchinson Cancer Center | 12 | 2012-03-01 | 2014-04-21 |
| A Trial of FANG™ Vaccine for Participants With Ovarian Cancer Vigil™ - Ovarian Cancer | Phase 2 | Completed | Gradalis, Inc. | 39 | 2011-03-08 | 2025-06-08 |
| Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas Celebrex, Tumor cell vaccine - Mesolthelioma, Esophageal Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 44 | 2010-12-01 | 2019-12-03 |
| Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. BF2.649, Vigil, palcebo - Treatment of Excessive Daytime Sleepiness in Narcolepsy | Phase 3 | Completed | Bioprojet | 180 | 2010-11-01 | 2017-01-31 |
| Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer Vigil™ - Ewings Sarcoma, Non Small Cell Lung Cancer | Phase 1 | Completed | Gradalis, Inc. | 100 | 2009-12-01 | 2022-03-15 |
| Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant autologous tumor cell vaccine, peripheral blood lymphocyte therapy - Leukemia, Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 | 2007-04-01 | 2014-03-21 |
| Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma autologous tumor cell vaccine, sargramostim, therapeutic autologous dendritic cells - Melanoma (Skin) | Phase 2 | Completed | Hoag Memorial Hospital Presbyterian | 200 | 2006-12-01 | 2014-01-10 |
| Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia autologous tumor cell vaccine, rituximab, cyclophosphamide - Leukemia | Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2006-08-01 | 2012-05-03 | |
| Vaccine Therapy in Treating Patients With Stage IV Melanoma autologous tumor cell vaccine, therapeutic autologous dendritic cells - Melanoma (Skin) | Phase 1 / Phase 2 | Unknown | Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen | 30 | 2005-04-01 | 2013-09-17 |
| Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer autologous tumor cell vaccine, therapeutic autologous dendritic cells, adjuvant therapy - Lung Cancer | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 15 | 2005-02-01 | 2008-01-28 |
Showing 20 of 41. Sign in to see all of them.
Melanoma (7) · Ovarian Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (5) · Leukemia (4) · Sarcoma, Ewing (4) · Astrocytoma (3) · Carcinoma, Renal Cell (3) · Central Nervous System Neoplasms (3) · Glioblastoma (3) · Gliosarcoma (3) · Kidney Neoplasms (3) · Multiple Myeloma (3) · Neoplasms (3) · Uterine Cervical Neoplasms (3)
Gradalis, Inc. (9) · Barbara Ann Karmanos Cancer Institute (3) · National Cancer Institute (NCI) (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Dartmouth-Hitchcock Medical Center (2) · AVAX Technologies (1) · Bioprojet (1) · Boston Medical Center (1) · Dana-Farber Cancer Institute (1) · Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen (1) · Fondren Orthopedic Group L.L.P. (1) · Fred Hutchinson Cancer Center (1) · Genuine Research Center, Egypt (1) · Gynecologic Oncology Group (1) · Hadassah Medical Organization (1)
United States (36) · Australia (1) · Canada (1) · Egypt (1) · France (1) · Germany (1) · Israel (1)
John Nemunaitis, MD (6) · Luisa Manning, MD (2) · Minal Barve, MD (2) · Adam Lerner, MD (1) · Ahmed Elshafeey, Ph.D. Pharma (1) · Andrew E. Sloan, MD (1) · Carol A. Huff, MD (1) · Charles L. Wiseman, MD, FACP (1) · Christopher P. Tretter, MD (1) · David Berd, MD (1) · David S Schrump, M.D. (1) · Dimitar Sajkov, MBBS/PhD (1) · Esteban Abella, MD (1) · Gerold Schuler (1)
PMID 33364285, PMID 34452019, PMID 16817692, PMID 17339422, PMID 19622576, PMID 22186789, PMID 22996370, PMID 25917459, PMID 27109631, PMID 27678295, PMID 31406564, PMID 32316978, PMID 33271095, PMID 33715892, PMID 33753870, PMID 4326367, PMID 8368765, PMID 9647171
P30CA006973 (3), P30CA022453 (3), K12CA076930 (1), P01CA015396 (1), P01CA068484 (1), P30CA006516 (1), P30CA023108 (1), R01CA095648 (1)